滋肾润肺方联合化疗对晚期肺癌的临床疗效

ffiClinical efficacy of Zishen Runfei prescription combined with chemotherapy in the treatment of advanced lung cancer

目的 探究滋肾润肺方联合化疗对晚期肺癌的临床疗效。方法 选取2019年10月-2021年10月滁州市第一人民医院收治的86例中晚期肺癌患者为研究对象,采用随机数字表法分为试验组和对照组,各43例。对照组采用紫杉醇注射液联合顺铂治疗,试验组在对照组基础上采用滋肾润肺方治疗。治疗3个月后,比较2组的中医证候评分、疾病控制率、肿瘤标志物水平[细胞角蛋白19片段抗21-1(CYFRA21-1)、癌胚抗原(CEA)]、不良反应及预后。结果 治疗后,2组中医证候积分均降低,且试验组低于对照组(P<0.05)。试验组疾病控制率优于对照组(P<0.05)。治疗后,2组血清CYFRA21-1、CEA水平均降低,试验组血清CYFRA21-1、CEA水平均低于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。随访1年,对照组失访1例,试验组失访2例,随访率为93.02%。对照组存活26例,试验组存活35例,2组生存曲线比较,差异有统计学意义(P<0.005)。结论 滋肾润肺方联合化疗有助于缓解中晚期肺癌气阴两虚证患者的症状,降低肿瘤标志物,远期疗效确切。

Objective To explore the clinical efficacy of Zishen Runfei prescription combined with chemotherapy in the treatment of advanced lung cancer.Methods 86 patients with mid-stage and late-stage lung cancer admitted to the First People's Hospital of Chu Zhou from October 2019 to October 2021 were selected and divided into the experiment group and the control group according to random number table method,with 43 cases in each group.The control group was treated with paclitaxel injection and cisplatin,while the experiment group was treated with Zishen Runfei prescription on the basis of the treatment of the control group.After 3 months of treatment,the traditional Chinese medicine(TCM)syndrome scores,disease control rates,tumor marker levels[cytokeratin-19 fragment(CYFRA21-1),carcinoembryonic antigen(CEA)],adverse reactions,and prognosis were compared between two groups.Results After treatment,TCM syndrome scores of both groups decreased,and the experiment group was lower than the control group(P<0.05).The disease control rate of the experiment group was better than that of the control group(P<0.05).After treatment,serum CYFRA21-1 and CEA levels in two groups decreased,and serum CYFRA21-1 and CEA levels in the experiment group were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between two groups(P>0.05).After 1 year of follow-up,1 case was lost to follow-up in the control group,2 cases were lost to follow-up in the experiment group,with the follow-up rate of 93.02%.26 patients survived in the control group,and 35 patients survived in the experiment group.There was statistically signigicant difference in the survival curves between two groups(P<0.05).Conclusion Zishen Runfei prescription combined with chemotherapy can help relieve the symptoms of patients with syndrome of deficiency of both qi and yin in mid-stage and late-stage lung cancer,reduce tumor marker levels,and achieve definite long-term efficacy.